<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617861</url>
  </required_header>
  <id_info>
    <org_study_id>18-003744</org_study_id>
    <secondary_id>R01DK115950</secondary_id>
    <secondary_id>R01DK122280</secondary_id>
    <secondary_id>UL1TR002377</secondary_id>
    <nct_id>NCT03617861</nct_id>
  </id_info>
  <brief_title>Effect of Secretin in Functional Dyspepsia and Healthy Subjects</brief_title>
  <official_title>Effect of Secretin on Gastric Accommodation, Emptying and Post-nutrient Challenge Symptoms in Functional Dyspepsia and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insights into the pathophysiology of functional dyspepsia, with recent demonstration of
      inflammation with eosinophilia and mastocytosis in the duodenum (3, 6, 7), providing a
      possible lead toward reduced secretion of a potential mediator of post-prandial gastric
      accommodation, the gastrointestinal peptide hormone secretin. The dominant site of synthesis
      and secretion of this hormone are enteroendocrine S cells in the duodenum.
      Inflammation-induced damage to these cells could produce a deficiency. Since intraluminal
      acid is a prominent stimulant of S cell secretion, the attempts to treat functional dyspepsia
      with anti-secretory medications could actually exacerbate a secretin deficiency syndrome.
      This raises the possibility of the therapeutic use of a secretin agonist or a positive
      allosteric modulator of the secretin receptor for patients with functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will utilize single photon emission computed tomography (SPECT) methodology
      and gamma scintigraphy present in the GI laboratory of the outpatient Clinical Research Unit
      to study fasting gastric volumes and postprandial gastric accommodation responses and gastric
      emptying rates of a standardized meal in patients with functional dyspepsia and healthy
      subjects. Both groups will be studied twice, using crossover design, once with administration
      of secretin and once with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Satiation</measure>
    <time_frame>60 minutes</time_frame>
    <description>Thirty (30) minutes after ingesting the meal of 300 mL radio-labeled Ensure drink, an additional Ensure drink was ingested at a constant rate of 30 mL/min until maximum tolerated volume was reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Gastric Volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Gastric fasting volume was measured prior to a meal of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Volume</measure>
    <time_frame>15 minutes</time_frame>
    <description>Postprandial volume was measured 15 minutes after ingestion of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gastric Accommodation</measure>
    <time_frame>Baseline, 30 minutes</time_frame>
    <description>The change in gastric accommodation was measured in mL using the difference between the fasting gastric volume and the postprandial volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric Emptying</measure>
    <time_frame>30 minutes</time_frame>
    <description>Gastric emptying was measured via scintigraphy 30 minutes after ingestion of 300 mL of radio-labeled Ensure drink and was reported as the percentage of the radio-labeled liquid meal emptied from the stomach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Postprandial Symptoms</measure>
    <time_frame>Baseline, 30 minutes</time_frame>
    <description>30 minutes after ingesting a meal of 300 mL of Ensure drink postprandial symptoms of fullness, nausea, bloating and pain were measured using a horizontal visual analog scales from 0 to 100, where 0 was 'none' and 100 was 'worst ever'.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Controls: Secretin Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls: Placebo Then Secretin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Dyspepsia: Secretin Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Dyspepsia: Placebo Then Secretin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Secretin</intervention_name>
    <description>Injected once over one minute</description>
    <arm_group_label>Functional Dyspepsia: Placebo Then Secretin</arm_group_label>
    <arm_group_label>Functional Dyspepsia: Secretin Then Placebo</arm_group_label>
    <arm_group_label>Healthy Controls: Placebo Then Secretin</arm_group_label>
    <arm_group_label>Healthy Controls: Secretin Then Placebo</arm_group_label>
    <other_name>ChiRhoStim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injected once over one minute</description>
    <arm_group_label>Functional Dyspepsia: Placebo Then Secretin</arm_group_label>
    <arm_group_label>Functional Dyspepsia: Secretin Then Placebo</arm_group_label>
    <arm_group_label>Healthy Controls: Placebo Then Secretin</arm_group_label>
    <arm_group_label>Healthy Controls: Secretin Then Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with FD and prior documentation of normal or accelerated gastric emptying and/or
        reduced gastric accommodation.

        Inclusion criteria:

          -  Able to provide written informed consent prior to any study procedures and be willing
             and able to comply with study procedures

          -  No medical problems or chronic diseases, other than functional dyspepsia, for that
             group

          -  Body mass index of 18-35 kg/m2

          -  Female subjects must have negative urine pregnancy tests and must not be lactating
             prior to receiving study medication and radiation exposure. For females able to bear
             children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier
             method, or a double-barrier method of birth control must be used throughout the study.
             Female subjects unable to bear children must have this documented in the medical
             record [i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum
             of one year since the last menstrual period)].

        Exclusion criteria:

          -  Unable or unwilling to provide informed consent or to comply with study procedures

          -  Diagnosis of other gastrointestinal diseases besides functional dyspepsia

          -  Structural or metabolic diseases that affect the GI system

          -  Unable to avoid the following over-the-counter medications 48 hours prior to the
             baseline period and throughout the study:

               -  Medications that alter GI transit or motor function including laxatives,
                  magnesium and aluminum containing antacids, prokinetics, erythromycin, buspirone,
                  clonidine, tricyclic antidepressants, and secretin-norepinephrine reuptake
                  inhibitors

               -  Analgesic drugs including NSAIDs and COX-2 inhibitors

               -  NOTE: Stable doses of thyroid replacement, estrogen replacement, low-dose aspirin
                  for cardio-protection, low stable dose antidepressants of the SSRI class, and
                  birth control (but with adequate backup contraception, as drug interactions with
                  birth control have not been conducted) are permissible.

          -  History of recent surgery (within 60 days of screening)

          -  Acute or chronic illness or history of illness which in the opinion of the
             investigator could pose a threat or harm to the subject or obscure interpretation of
             laboratory test results or interpretation of study data, such as frequent angina,
             Class III or IV congestive heart failure, moderate impairment of renal or hepatic
             function, poorly controlled diabetes, etc.

          -  Any clinically significant abnormalities on physical examination or laboratory
             abnormalities identified in the medical record, as determined by the investigator

          -  Acute GI illness within 48 hours of initiation of the baseline period

          -  Females who are pregnant or breastfeeding

          -  History of excessive alcohol use or substance abuse

          -  Participation in an investigational study within the 30 days prior to dosing in the
             present study

          -  Any other reason, which in the opinion of the investigator, would confound proper
             interpretation of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Brandler J, Miller LJ, Wang XJ, Burton D, Busciglio I, Arndt K, Harmsen WS, Camilleri M. Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. Am J Physiol Gastrointest Liver Physiol. 2020 Apr 1;318(4):G635-G645. doi: 10.1152/ajpgi.00371.2019. Epub 2020 Feb 10.</citation>
    <PMID>32036693</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>May 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Camilleri, MD</investigator_full_name>
    <investigator_title>Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03617861/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls: Secretin Then Placebo</title>
          <description>Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline matching Secretin dose) via IV over 1 min on Visit Day 2.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls: Placebo Then Secretin</title>
          <description>Healthy subjects first receive placebo treatment (normal saline matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.</description>
        </group>
        <group group_id="P3">
          <title>Functional Dyspepsia: Secretin Then Placebo</title>
          <description>Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline matching Secretin dose) via IV over 1 min on Visit Day 2.</description>
        </group>
        <group group_id="P4">
          <title>Functional Dyspepsia: Placebo Then Secretin</title>
          <description>Functional Dyspepsia subjects first receive placebo treatment (normal saline matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 to 4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Healthy controls were randomly assigned to secretin or placebo allocation before treatment. After a 1 to 4 week washout period, they received the alternate treatment from that administered on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Functional Dyspepsia</title>
          <description>Functional Dyspepsia subjects were randomly assigned to secretin or placebo allocation before treatment. After a 1 to 4 week washout period, they received the alternate treatment from that administered on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" lower_limit="38.0" upper_limit="49.0"/>
                    <measurement group_id="B2" value="50.5" lower_limit="42.0" upper_limit="55.0"/>
                    <measurement group_id="B3" value="47.0" lower_limit="40.0" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Satiation</title>
        <description>Thirty (30) minutes after ingesting the meal of 300 mL radio-labeled Ensure drink, an additional Ensure drink was ingested at a constant rate of 30 mL/min until maximum tolerated volume was reached.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Satiation</title>
          <description>Thirty (30) minutes after ingesting the meal of 300 mL radio-labeled Ensure drink, an additional Ensure drink was ingested at a constant rate of 30 mL/min until maximum tolerated volume was reached.</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="892.5" lower_limit="892.5" upper_limit="1011"/>
                    <measurement group_id="O2" value="951.75" lower_limit="892.5" upper_limit="1129.5"/>
                    <measurement group_id="O3" value="655.5" lower_limit="537" upper_limit="774"/>
                    <measurement group_id="O4" value="892.5" lower_limit="655.5" upper_limit="1011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0574</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Gastric Volume</title>
        <description>Gastric fasting volume was measured prior to a meal of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Gastric Volume</title>
          <description>Gastric fasting volume was measured prior to a meal of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.28" lower_limit="146.17" upper_limit="189.39"/>
                    <measurement group_id="O2" value="152.96" lower_limit="145.5" upper_limit="161.04"/>
                    <measurement group_id="O3" value="227" lower_limit="186.7" upper_limit="251.2"/>
                    <measurement group_id="O4" value="210.2" lower_limit="179.38" upper_limit="240.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1451</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postprandial Volume</title>
        <description>Postprandial volume was measured 15 minutes after ingestion of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
        <time_frame>15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Volume</title>
          <description>Postprandial volume was measured 15 minutes after ingestion of 300 mL standardized radio-labeled Ensure drink using an intravenous injection of Technetium Tc-99m pertechnetate and noninvasive single photon emission-computed tomography (SPECT).</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.85" lower_limit="384.70" upper_limit="647.71"/>
                    <measurement group_id="O2" value="457.43" lower_limit="329.39" upper_limit="495.01"/>
                    <measurement group_id="O3" value="593.80" lower_limit="557.85" upper_limit="637.90"/>
                    <measurement group_id="O4" value="582.36" lower_limit="546.51" upper_limit="631.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4233</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Gastric Accommodation</title>
        <description>The change in gastric accommodation was measured in mL using the difference between the fasting gastric volume and the postprandial volume.</description>
        <time_frame>Baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Accommodation</title>
          <description>The change in gastric accommodation was measured in mL using the difference between the fasting gastric volume and the postprandial volume.</description>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.44" lower_limit="221.97" upper_limit="468.01"/>
                    <measurement group_id="O2" value="271.01" lower_limit="194.74" upper_limit="343.62"/>
                    <measurement group_id="O3" value="378.6" lower_limit="339.42" upper_limit="404.18"/>
                    <measurement group_id="O4" value="370.2" lower_limit="339.09" upper_limit="382.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3891</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastric Emptying</title>
        <description>Gastric emptying was measured via scintigraphy 30 minutes after ingestion of 300 mL of radio-labeled Ensure drink and was reported as the percentage of the radio-labeled liquid meal emptied from the stomach.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying</title>
          <description>Gastric emptying was measured via scintigraphy 30 minutes after ingestion of 300 mL of radio-labeled Ensure drink and was reported as the percentage of the radio-labeled liquid meal emptied from the stomach.</description>
          <units>percentage of gastric emptying</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="19.0" lower_limit="15.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="8.0" lower_limit="2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Healthy Secretin vs Healthy Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Healthy vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0355</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Postprandial Symptoms</title>
        <description>30 minutes after ingesting a meal of 300 mL of Ensure drink postprandial symptoms of fullness, nausea, bloating and pain were measured using a horizontal visual analog scales from 0 to 100, where 0 was 'none' and 100 was 'worst ever'.</description>
        <time_frame>Baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls: Secretin</title>
            <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls: Placebo</title>
            <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O3">
            <title>Functional Dyspepsia: Secretin</title>
            <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min on either the first or second study visit day.</description>
          </group>
          <group group_id="O4">
            <title>Functional Dyspepsia: Placebo</title>
            <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min on either the first or second study visit day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Postprandial Symptoms</title>
          <description>30 minutes after ingesting a meal of 300 mL of Ensure drink postprandial symptoms of fullness, nausea, bloating and pain were measured using a horizontal visual analog scales from 0 to 100, where 0 was 'none' and 100 was 'worst ever'.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="10" lower_limit="8" upper_limit="28"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fullness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="31" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O4" value="11" lower_limit="5" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="24" lower_limit="6" upper_limit="34"/>
                    <measurement group_id="O4" value="26" lower_limit="8" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="19"/>
                    <measurement group_id="O4" value="10" lower_limit="5" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea: Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Nausea: Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Nausea: Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fullness: Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Fullness: Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Fullness: Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bloating: Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bloating Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Bloating: Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0330</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abdominal Pain: Healthy Controls Secretin vs Healthy Controls Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdominal Pain: Functional Dyspepsia Secretin vs Functional Dyspepsia Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdominal Pain: Healthy Controls vs Functional Dyspepsia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2375</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be collected on each patient for each of the two individual study days, over a total duration of approximately one year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Controls: Secretin</title>
          <description>Healthy controls who received human Secretin 0.2 mcg/kg via IV over 1 min.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls: Placebo</title>
          <description>Healthy controls who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min.</description>
        </group>
        <group group_id="E3">
          <title>Functional Dyspepsia: Secretin</title>
          <description>Functional Dyspepsia subjects who received human Secretin 0.2 mcg/kg via IV over 1 min.</description>
        </group>
        <group group_id="E4">
          <title>Functional Dyspepsia: Placebo</title>
          <description>Functional Dyspepsia subjects who received placebo treatment (normal saline matching Secretin dose) via IV over 1 min.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Postprandial fullness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Camilleri, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2305</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

